SEC Form 4 · accession 0000919574-18-008212
Strongbridge Biopharma plc · SBBP
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Period of report
Dec 26, 2018
Accepted (ET)
Dec 28, 2018 · 5:39 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001634432
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary Shares, $0.01 par valueF1 | Dec 26, 2018 | P | 31,197 | $3.9971 | A | 6,563,105 | D | |
| Ordinary Shares, $0.01 par valueF1 | Dec 27, 2018 | P | 18,200 | $3.9799 | A | 6,581,305 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Following the transactions reported herein, these shares represent (a) 6,244,501 Ordinary Shares that are owned directly by CDK Associates, LLC, which is a reporting person, and may be deemed to be indirectly beneficially owned by (i) Caxton Corporation, the manager of CDK Associates, LLC, and (ii) Bruce Kovner, the chairman and sole shareholder of Caxton Corporation; and (b) 336,804 Ordinary Shares beneficially owned by employees of an affiliate of Caxton Corporation and may be deemed to be indirectly beneficially owned by (i) Caxton Corporation and (ii) Bruce Kovner, the chairman and sole shareholder of Caxton Corporation.
Remarks
Each Reporting Person disclaims beneficial ownership in the securities reported on this Form 4 except to the extent of its or his pecuniary interest, if any, therein, and this report shall not be deemed to be an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.